Pfizer outlines Talzenna's survival benefit in bid for broad prostate cancer approval
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug's already broadest-in-class U.S. label in prostate cancer.
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug's already broadest-in-class U.S. label in prostate cancer.
